Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine

AIDS Patient Care and STDs

Volumn 16, Issue 2, 2002, Pages 67-73

  Zaccarelli, Mauro ^a   Barracchini, A ^a   De Longis, P ^a   Perno, C F ^a   Soldani, F ^a   Liuzzi, G ^a   Serraino, D ^a   Ippolito, G ^a   Antinori, A ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DEMOGRAPHY; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; RASH; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE; TREATMENT PLANNING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEASIBILITY STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT FAILURE;

EID: 0036181518     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/10872910252806117     Document Type: Article

References (24)

1. Understanding the dynamics of the HIV epidemic among Italian intravenous drug users: A cross-sectional versus a longitudinal approach
2. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: Results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study
3. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
4. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
5. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy
6. Psychoactive drug use and progression of HIV infection
7. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
8. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
9. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
10. Preliminary results of a randomized multicenter study comparing combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE study)
11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
12. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
13. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
14. Once-daily therapy (NVP/ddI/3TC) for the IVDU HIV-1 infected population of the Frankfurt HIV-Cohort
15. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids
16. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment
17. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy
18. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
19. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert
20. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
21. Methadone withdrawal when starting an antiretroviral regimen including nevirapine